ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference
(Thomson Reuters ONE) -
Presentation highlights the use of ProMIS' proprietary discovery platform to
identify novel therapeutic targets on misfolded proteins in multiple
neurodegenerative diseases
TORONTO and CAMBRIDGE, Mass., Sept. 28, 2017 (GLOBE NEWSWIRE) -- ProMIS
Neurosciences, Inc., a biotechnology company focused on the discovery and
development of precision treatments for neurodegenerative diseases, announced
that Neil Cashman, MD, Professor and Canada Research Chair, University of
British Columbia and Chief Scientific Officer, ProMIS Neurosciences, will
present today at the 3rd Annual Neuroscience R&D Technologies
Conference: Exploring Cutting-edge Technologies in Pre-clinical Neuroscience
Studies.
Dr. Cashman's presentation, entitled Misfolding Proteins in Neurodegenerative
Diseases describes the roles of toxic misfolded proteins as underlying drivers
of multiple neurodegenerative diseases, including Alzheimer's disease and
amyotrophic lateral sclerosis (ALS).
Commenting on the presentation, Eugene Williams, ProMIS Executive Chairman,
stated, "We are delighted with the international recognition Neil Cashman is
receiving for his important work in neurodegenerative diseases. Using ProMIS'
proprietary discovery platform across a range of neurodegenerative diseases, Dr.
Cashman and our team have identified novel therapeutic targets on toxic
misfolded proteins, including Amyloid beta oligomers in Alzheimer's disease,
TDP43 in ALS, and alpha synuclein in Parkinson's disease. Antibodies selectively
binding these novel targets, such as ProMIS' validated lead product candidate
for Alzheimer's disease, PMN310, offer an exciting approach to the development
of potential best-in-class therapeutics."
The 3rd Annual Neuroscience R&D Technologies Conference, to be held in London,
UK, September 28-29, 2017, is focused on sharing current market trends,
technological advancements, and future challenges in pre-clinical neuroscience
research. The conference gathers leading experts from the pharmaceutical
industry and research institutes to evaluate the latest technologies in
neuroscience R&D with expert keynote presentations, live case studies, and
breakthrough panel discussions.
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a TSX listed biotechnology company (trading symbol:
PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge,
Massachusetts. The mission of ProMIS is to discover and develop precision
medicine therapeutics for effective treatment of neurodegenerative diseases, in
particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of
two, complementary techniques. The Company applies its thermodynamic,
computational discovery platform-ProMIS(TM) and Collective Coordinates - to
predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular
surface of misfolded proteins. Using this unique "precision medicine" approach,
ProMIS Neurosciences is developing novel antibody therapeutics and specific
companion diagnostics for Alzheimer's disease and ALS. In addition, ProMIS
Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to
misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody
therapeutic against this target.
The TSX has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release. This information release may contain certain forward-
looking information. Such information involves known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by statements herein,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on the
Company's current beliefs as well as assumptions made by and information
currently available to it as well as other factors. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date of this press release. Due to risks and uncertainties, including the
risks and uncertainties identified by the Company in its public securities
filings, actual events may differ materially from current expectations. The
Company disclaims any intention or obligation to update or revise any forward-
looking statements, whether as a result of new information, future events or
otherwise.
For further information please consult the Company's website at:
www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
For media inquiries, please contact:
Scott Santiamo
RussoPartners/LLC
Scott.Santiamo(at)russopartnersllc.com
Tel. 718 344-5843
David Schull
RussoPartners/LLC
David.Schull(at)russopartnersllc.com
Tel. 858 717-2310
For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick(at)alpineequityadv.com
Tel. 617 901-0785
Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Elliot.goldstein(at)promisneurosciences.com
Tel. 415 341-5783
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 28.09.2017 - 13:30 Uhr
Sprache: Deutsch
News-ID 561776
Anzahl Zeichen: 6314
contact information:
Town:
Toronto
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 226 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
ProMIS Neurosciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
